Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.
Sponsor: Walter Reed National Military Medical Center
Summary
The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury. The main questions it aims to answer are: Does adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)? Researchers will compare: Standard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function. (Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.) Participants will: Be randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint Be followed after surgery to measure: Pain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function
Official title: Adjunctive Use of Corticosteroid in Periarticular Injections in Primary Total Knee Arthroplasty
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2025-09-01
Completion Date
2026-08-31
Last Updated
2025-09-03
Healthy Volunteers
No
Interventions
PAI
Standard PAI: 30 mg Toradol/ketorolac (30mg/ml), 49.25ml 0.5% ropivacaine (5mg/ml), and 0.5 mg
PAI + steroid
Standard PAI + 40mg methylprednisolone (n = 40)
PAI + zilretta
Standard PAI + 32mg Zilretta (triamcinolone acetonide extended release injectable suspension)
Locations (1)
Walter Reed National Military Medical Center
Bethesda, Maryland, United States